WeTrials
Recruiting

A Multicenter, Open-label, First-in-Human Study of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations

What is this study?

This study is testing a new, investigational medicine called TYRA-430 for adults with advanced liver cancer and other solid tumors. It is designed for cancers that have specific changes in their genes, known as FGF or FGFR aberrations.

Who can participate?

You may be able to join if you are 18 or older, can take pills by mouth, and are well enough to perform daily activities. Your vital organs must be working well, and your cancer should not be curable with standard local treatments like surgery.

What will happen?

Participants will take the investigational study medication, TYRA-430, as a pill by mouth. The study team will closely monitor your health, check for side effects, and see how well the treatment works against your tumor.

Where and when?

This study is currently recruiting participants at locations in Los Angeles, San Francisco, and Stanford, California. It is a Phase 1 study, meaning it is the very first time this medication is being tested in humans.

Key Points
  • 1Tests a new targeted pill called TYRA-430 for advanced solid tumors and liver cancer
  • 2Requires specific genetic changes in the FGF/FGFR pathway to qualify
  • 3Currently active and recruiting patients at multiple locations in California

No related links yet

Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Metastatic Hepatocellular CarcinomaSolid TumorsSolid Tumor, AdultFGFR Gene AmplificationFGFR Gene AlterationsAdvanced Solid TumorsFGFR4 Gene MutationFGFR4 Gene FusionsFGF19 Gene AmplificationFGF19 Gene OverexpressionLocally Advanced Unresectable Hepatocellular Carcinoma

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.